Soul JS, Bergin AM, Stopp C, Hayes B. Singh A, Rosa Fortuno C, O'Reilly D, Krishnamoorthy K, Jensen FE. Rofeberg V, Dong M, Vinks A, Wypij D, Staley K for the Boston Bumetanide Trial Group. A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures. Controlled bumetanide trial for neonatal seizures. Annals of Neurology |November 18, 2020
In the first trial to include a standard‐therapy control group, this study was undertaken to investigate bumetanide added to phenobarbital to treat neonatal seizures. Researchers randomized individuals with EEG‐confirmed seizures after ≥ 20 and < 40 mg/kg phenobarbital to receive additional phenobarbital with either placebo (control) or 0.1, 0.2, or 0.3mg/kg bumetanide (treatment). Individuals were assigned randomly to treatment (n=27) and control (n=16) groups. This randomized, controlled, multicenter trial indicated a drop in seizure burden that can be attributed to bumetanide over phenobarbital with no increase in serious adverse effects. Definitive proof of efficacy needs an appropriately powered phase 3 trial, and further evaluations of bumetanide and other drugs should include a control group and balance seizure severity.
Courtesy of: https://www.mdlinx.com/journal-summary/a-pilot-randomized-controlled-double-blind-trial-of-bumetanide-to-treat-neonatal-seizures-controlled/27pSoiGDTvSo85KsZSqAkg